Skip to main content
Top
Published in: Journal of Cancer Survivorship 4/2020

01-08-2020

Medical conditions and physical function deficits among multiple primary cancer survivors

Authors: Chelsea Anderson, Susan M. Gapstur, Corinne R. Leach, Tenbroeck G. Smith, Lauren R. Teras

Published in: Journal of Cancer Survivorship | Issue 4/2020

Login to get access

Abstract

Purpose

Survivors of multiple primary cancers make up a sizable proportion of all cancer survivors, yet little is known about the health of this population. We examined the prevalence of medical conditions and physical function deficits among multiple primary survivors compared with single primary survivors and individuals without a cancer history.

Methods

Participants were enrolled in the Cancer Prevention Study (CPS)-II Nutrition Cohort in 1992/1993. Prevalent medical conditions (diabetes, heart conditions, cerebrovascular conditions, emphysema/chronic bronchitis, osteoporosis, osteoarthritis), physical function limitations, use of a cane or walker, balance difficulties, and falls within the past year were assessed on a follow-up survey completed in 2011. We estimated age- and sex-adjusted prevalence ratios (PRs), comparing multiple primary survivors (N = 1003) to single primary survivors (N = 12,849) and participants without cancer (N = 63,578).

Results

The prevalence of medical conditions did not differ substantially between multiple primary survivors and either comparison group. However, multiple primary survivors were more likely to report severe limitations in physical function than the single primary (PR = 1.48 (95% CI, 1.28–1.71)) and no-cancer (PR = 1.64 (95% CI, 1.42–1.88)) groups. Using a cane or walker and balance difficulties were also significantly more common among multiple primary survivors.

Conclusions

Despite a similar prevalence of comorbid medical conditions, severe functional limitations were significantly more common among multiple primary survivors than single primary survivors or individuals without cancer.

Implications for Cancer Survivors

Assessment of functional status and treatment of physical deficits may be an especially critical component of care for older patients with a history of multiple cancer diagnoses.
Appendix
Available only for authorised users
Literature
1.
go back to reference American Cancer Society. Cancer treatment & survivorship facts & figures 2019–2021. Atlanta: American Cancer Society; 2019. American Cancer Society. Cancer treatment & survivorship facts & figures 2019–2021. Atlanta: American Cancer Society; 2019.
3.
go back to reference Working Group Report. International rules for multiple primary cancers (ICD-0 third edition). Eur J Cancer Prev. 2005;14(4):307–8.CrossRef Working Group Report. International rules for multiple primary cancers (ICD-0 third edition). Eur J Cancer Prev. 2005;14(4):307–8.CrossRef
11.
go back to reference Thong MS, Mols F, Verhoeven RH, Liu L, Andrykowski MA, Roukema JA, et al. Multiple primary cancer survivors have poorer health status and well-being than single primary cancer survivors: a study from the population-based PROFILES registry. Psychooncology. 2013;22(8):1834–42. https://doi.org/10.1002/pon.3227.CrossRefPubMed Thong MS, Mols F, Verhoeven RH, Liu L, Andrykowski MA, Roukema JA, et al. Multiple primary cancer survivors have poorer health status and well-being than single primary cancer survivors: a study from the population-based PROFILES registry. Psychooncology. 2013;22(8):1834–42. https://​doi.​org/​10.​1002/​pon.​3227.CrossRefPubMed
Metadata
Title
Medical conditions and physical function deficits among multiple primary cancer survivors
Authors
Chelsea Anderson
Susan M. Gapstur
Corinne R. Leach
Tenbroeck G. Smith
Lauren R. Teras
Publication date
01-08-2020
Publisher
Springer US
Published in
Journal of Cancer Survivorship / Issue 4/2020
Print ISSN: 1932-2259
Electronic ISSN: 1932-2267
DOI
https://doi.org/10.1007/s11764-020-00872-0

Other articles of this Issue 4/2020

Journal of Cancer Survivorship 4/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine